

# The NEW ENGLAND JOURNAL of MEDICINE

## A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

Marc A. Pfeffer, M.D., Ph.D., Emmanuel A. Burdmann, M.D., Ph.D., Chao-Yin Chen, Ph.D., Mark E. Cooper, M.D., Dick de Zeeuw, M.D., Ph.D., Kai-Uwe Eckardt, M.D., Jan M. Feyzi, M.S., Peter Ivanovich, M.D., Reshma Kewalramani, M.D., Andrew S. Levey, M.D., Eldrin F. Lewis, M.D., M.P.H., Janet B. McGill, M.D., John J.V. McMurray, M.D., Patrick Parfrey, M.D., Hans-Henrik Parving, M.D., Giuseppe Remuzzi, M.D., Ajay K. Singh, M.D., Scott D. Solomon, M.D., and Robert Toto, M.D., for the TREAT Investigators\*

### ABSTRACT

#### BACKGROUND

Anemia is associated with an increased risk of cardiovascular and renal events among patients with type 2 diabetes and chronic kidney disease. Although darbepoetin alfa can effectively increase hemoglobin levels, its effect on clinical outcomes in these patients has not been adequately tested.

#### METHODS

In this study involving 4038 patients with diabetes, chronic kidney disease, and anemia, we randomly assigned 2012 patients to darbepoetin alfa to achieve a hemoglobin level of approximately 13 g per deciliter and 2026 patients to placebo, with rescue darbepoetin alfa when the hemoglobin level was less than 9.0 g per deciliter. The primary end points were the composite outcomes of death or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and of death or end-stage renal disease.

#### RESULTS

Death or a cardiovascular event occurred in 632 patients assigned to darbepoetin alfa and 602 patients assigned to placebo (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% confidence interval [CI], 0.94 to 1.17;  $P=0.41$ ). Death or end-stage renal disease occurred in 652 patients assigned to darbepoetin alfa and 618 patients assigned to placebo (hazard ratio, 1.06; 95% CI, 0.95 to 1.19;  $P=0.29$ ). Fatal or nonfatal stroke occurred in 101 patients assigned to darbepoetin alfa and 53 patients assigned to placebo (hazard ratio, 1.92; 95% CI, 1.38 to 2.68;  $P<0.001$ ). Red-cell transfusions were administered to 297 patients assigned to darbepoetin alfa and 496 patients assigned to placebo ( $P<0.001$ ). There was only a modest improvement in patient-reported fatigue in the darbepoetin alfa group as compared with the placebo group.

#### CONCLUSIONS

The use of darbepoetin alfa in patients with diabetes, chronic kidney disease, and moderate anemia who were not undergoing dialysis did not reduce the risk of either of the two primary composite outcomes (either death or a cardiovascular event or death or a renal event) and was associated with an increased risk of stroke. For many persons involved in clinical decision making, this risk will outweigh the potential benefits. (ClinicalTrials.gov number, NCT00093015.)

The affiliations of the authors are listed in the Appendix. Address reprint requests to Dr. Pfeffer at the Cardiovascular Division, Brigham and Women's Hospital, 75 Francis St., Boston, MA 02115, or at [mpfeffer@rics.bwh.harvard.edu](mailto:mpfeffer@rics.bwh.harvard.edu).

\*The Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) committees and teams are listed in the Appendix, and investigators and individual sites are listed in the Supplementary Appendix, available with the full text of this article at [NEJM.org](http://NEJM.org).

This article (10.1056/NEJMoa0907845) was published on October 30, 2009, at [NEJM.org](http://NEJM.org).

*N Engl J Med* 2009;361.

Copyright © 2009 Massachusetts Medical Society.

**T**YPE 2 DIABETES MELLITUS AND CHRONIC kidney disease frequently coexist, and each disease independently increases the risk of cardiovascular events and end-stage renal disease.<sup>1,2</sup> Intensive treatment of concomitant conventional risk factors such as hypertension and elevated levels of low-density lipoprotein reduces fatal and nonfatal cardiovascular complications and slows the progression of kidney disease.<sup>3-8</sup> Observational studies suggest that anemia can be considered another biomarker of risk, since a lower hemoglobin level is independently associated with a higher rate of cardiovascular and renal events,<sup>9-11</sup> especially among patients with diabetes.<sup>12,13</sup> Whether the use of erythropoiesis-stimulating agents (ESAs) to increase hemoglobin levels lowers this risk is not known.<sup>14</sup>

Early studies involving the use of recombinant human erythropoietin in patients with severe anemia who were undergoing dialysis showed a reduced requirement for blood transfusions and improved quality-of-life assessments, which were considered major advances.<sup>15,16</sup> Extrapolations from these favorable effects to other populations, including patients with anemia and earlier stages of chronic kidney disease, led to the wider use of ESAs. The presumption of the benefits associated with the use of ESAs was so pervasive that major clinical trials considered the use of placebo unnecessary or even unethical.<sup>17-19</sup> In fact, there were no placebo-controlled trials in a recent meta-analysis of the use of ESAs in patients with chronic kidney disease.<sup>20</sup> Although ESAs have been available for more than two decades, the hypothesis that this treatment approach would lower the risks associated with anemia and improve the prognosis has not been examined.<sup>21</sup> We conducted the Trial to Reduce Cardiovascular Events with Aranesp Therapy (TREAT) to test the hypothesis that, in patients with type 2 diabetes, chronic kidney disease that does not require dialysis, and concomitant anemia, increasing hemoglobin levels with the use of this agent would lower the rates of death, cardiovascular events, and end-stage renal disease.<sup>22</sup>

## METHODS

The TREAT was a randomized, double-blind, placebo-controlled trial conducted at 623 sites in 24 countries (see the Supplementary Appendix, available with the full text of this article at NEJM.org). The institutional review board or ethics

committee at each site approved the protocol, and all patients provided written informed consent. Enrollment occurred from August 25, 2004, through December 4, 2007.

The trial was sponsored by Amgen and designed in collaboration with an academic executive committee. Data collection and management were the responsibility of the sponsor, with oversight by the executive committee. The Statistical Data Analysis Center at the University of Wisconsin prepared the interim unblinded reports for the independent data and safety monitoring committee, which oversaw patient safety and the quality of trial conduct. The independent academic statistical center also performed all analyses for this article and provided the writing group with unrestricted access to the data. The manuscript was prepared by the principal investigator and subsequently revised and edited by all the authors. All the authors decided to submit the article for publication and assume responsibility for the accuracy and completeness of the reported data.

## STUDY POPULATION

Patients with type 2 diabetes, chronic kidney disease (an estimated glomerular filtration rate [GFR] of 20 to 60 ml per minute per 1.73 m<sup>2</sup> of body-surface area, calculated with the use of the four-variable Modification of Diet in Renal Disease formula), anemia (hemoglobin level,  $\leq 11.0$  g per deciliter), and a transferrin saturation of 15% or more were eligible for enrollment. Patients with any of the following factors were excluded: uncontrolled hypertension; previous kidney transplantation or scheduled receipt of a kidney transplant from a living related donor; current use of intravenous antibiotics, chemotherapy, or radiation therapy; cancer (except basal-cell or squamous-cell carcinoma of the skin); diagnosed human immunodeficiency virus infection; active bleeding; a hematologic disease; or pregnancy. Patients who had had a cardiovascular event or grand mal seizure, had undergone major surgery, or had received an ESA in the 12 weeks before randomization were also ineligible.

## STUDY PROCEDURES

During a 2-week screening period, prestudy laboratory assessments were obtained and the eligibility of patients who had provided consent was confirmed. Patients were randomly assigned with the use of a computer-generated, permuted-block

design, in a 1:1 ratio, to receive darbepoetin alfa (Aranesp, Amgen) or placebo. Randomization was stratified according to the study site, the baseline level of proteinuria (with marked proteinuria defined as a ratio of total protein to creatinine [calculated in milligrams per deciliter] of  $\geq 1.0$  in a spot urine sample), and an investigator-designated history of cardiovascular disease. Darbepoetin alfa and placebo were supplied in matching pre-filled syringes at 12 different strengths. A third party used a point-of-care device to monitor hemoglobin levels and enter the value into an interactive voice-response system that selected the dosage according to a computer algorithm (see the Supplementary Appendix). This algorithm was designed to adjust the dose in order to maintain the hemoglobin level at approximately 13.0 g per deciliter in the patients assigned to darbepoetin alfa.

Patients in the placebo group were assigned to receive darbepoetin alfa as a rescue agent if the hemoglobin level fell below 9.0 g per deciliter, with a return to placebo once the hemoglobin level was 9.0 g per deciliter or higher. The site investigator was to be notified if any patient had a hemoglobin value of 7.0 g per deciliter or less, a value of 16.0 g per deciliter or more, or a decrease of 2.0 g per deciliter or more in a 4-week period.

Measurements of hemoglobin levels and vital signs were performed every 2 weeks during the study-drug-titration period and monthly thereafter. Transferrin saturation and ferritin levels were measured quarterly; other laboratory assessments and spot urine collections were performed at 24-week intervals. Patient-reported outcomes and health resource utilization were assessed at weeks 1, 13, and 25 and every 24 weeks thereafter. At each visit, information was gathered regarding adverse events, hospitalization, transfusions, and the concomitant use of other medications.

#### EVALUATION OF OUTCOMES

The primary end points were the time to the composite outcome of death from any cause or a cardiovascular event (nonfatal myocardial infarction, congestive heart failure, stroke, or hospitalization for myocardial ischemia) and the time to the composite outcome of death or end-stage renal disease (see the Supplementary Appendix). The overall alpha level for the primary end points was split: 0.048 for the cardiovascular composite outcome and 0.002 for the renal composite outcome. All potential end points were adjudicated

by a clinical end-point committee whose members were unaware of the treatment assignments, and the hematocrit and hemoglobin values were redacted from the documents under review. Important secondary end points included time to death, death from cardiovascular causes, and the components of the primary end points, as well as the rate of decline in the estimated GFR and changes in patient-reported outcomes at week 25 measured with the use of the Functional Assessment of Cancer Therapy–Fatigue (FACT–Fatigue) instrument (on which scores range from 0 to 52, with higher scores indicating less fatigue) and the 36-Item Short-Form General Health Survey questionnaire (calculated with norm-based scoring so that 50 is the average score, with higher scores indicating a better quality of life) (added after the second protocol amendment in May 2005).

#### MONITORING

The independent data and safety monitoring committee reviewed safety reports monthly with formal interim analyses scheduled when approximately 20, 40, 60, and 80% of the total expected cardiovascular composite events had occurred. Initial guidelines for early discontinuation included a symmetric O'Brien–Fleming alpha-spending function. In April 2006, data from a non-placebo-controlled trial of a different ESA in patients with chronic kidney disease showed that treatment aimed at achieving a higher hemoglobin level (13.5 g per deciliter vs. 11.3 g per deciliter) was associated with increased rates of adverse clinical events.<sup>17</sup> This information and more equivocal results from a related, smaller trial<sup>18</sup> were proactively communicated to our patients, investigators, and the data and safety monitoring committee. The committee made no recommendation to alter or terminate the study on the basis of interim data that already reflected more clinical events than the numbers of events in these related trials. The consent form was modified with the addition of the new information regarding potential harm, and all study participants were asked to provide written informed consent again. The executive committee requested that the data and safety monitoring committee adopt a more cautious stopping rule, with the use of a one-sided alpha of 0.05 for harm at each assessment (without adjustment for multiple testing) for either the cardiovascular composite outcome or death. The boundaries for efficacy remained unchanged, and with this new mandatory stop-

ping rule for harm, the committee made no recommendation to terminate the trial before its scheduled conclusion.

#### STATISTICAL ANALYSIS

The trial was event driven, with a total of 1203 cardiovascular composite events required to provide 80% statistical power to detect a 20% risk reduction for this outcome, with a two-sided type I error of 0.048 (unadjusted for interim analyses). We aimed to enroll approximately 4000 patients; assumptions included an annualized rate of events in the placebo group of 12.5%, a 15% loss to follow-up, and attenuation of the treatment effect due to the anticipated use of ESAs in patients who had progression to end-stage renal disease.

Time-to-event analyses were performed with the use of life-table methods according to the intention-to-treat principle. Kaplan–Meier cumulative incidence curves were compared with the use of a two-sided log-rank test, stratified according to the baseline proteinuria level and the presence or absence of a history of cardiovascular disease. Estimated hazard ratios (for darbepoetin alfa vs. placebo) and 95% confidence intervals were obtained with the use of stratified Cox proportional-hazards models. Patients who discontinued either study drug early, including patients who began treatment with dialysis or underwent transplantation, were followed for study end points.

Categorization of adverse events was based on groupings of preferred terms defined by the standardized queries in the Medical Dictionary for Regulatory Activities.<sup>23</sup> Analyses of patient-reported outcomes were prespecified to impute missing data with the last-observation-carried-forward method and to use t-tests for treatment comparisons, with means and standard deviations. Reported P values are nominal and have not been adjusted for multiple comparisons. Additional statistical methods are described in the Supplementary Appendix.

## RESULTS

#### PATIENTS

We enrolled a total of 4047 patients, but before unblinding, we excluded all information regarding 9 patients from two sites that did not adhere to Good Clinical Practice guidelines (4 patients who were randomly assigned to darbepoetin alfa and 5 patients who were randomly assigned to

placebo). Of the 4038 patients evaluated, 2012 were assigned to receive darbepoetin alfa and 2026 were assigned to receive placebo. The study was event driven and was completed on March 28, 2009, with a median follow-up duration of 29.1 months. At that time, 3523 patients (87.2%) were either still being followed for clinical end points or had died; this group included 1761 patients in the darbepoetin alfa group (87.5%) and 1762 patients in the placebo group (87.0%). The vital status at study termination was unknown for 153 patients in the darbepoetin alfa group (7.6%) and 164 in the placebo group (8.1%) (see the Consolidated Standards for the Reporting of Trials [CONSORT] diagram in the Supplementary Appendix).

The median age was 68 years, and 57.3% of the patients were women; 65.4% of the patients had a history of cardiovascular disease, with similar percentages of patients in each group reporting a history of coronary artery disease, stroke, peripheral arterial disease, and myocardial infarction. There was an imbalance in the proportion of patients with a history of heart failure (31.5% in the darbepoetin alfa group vs. 35.2% in the placebo group, unadjusted  $P=0.01$ ). There were no clinically meaningful baseline imbalances in vital signs, laboratory data, or the use of medications for cardiovascular disease and diabetes (Table 1).

#### INTERVENTION AND HEMOGLOBIN VALUES

The overall median hemoglobin level at baseline was 10.4 g per deciliter (interquartile range, 9.8 to 10.9). Between-group differences in hemoglobin values were apparent less than 1 month after randomization, and the differences were significant by 1 month (Fig. 1). From 3 months to the end of treatment, the median achieved hemoglobin level (based on the area under the curve) was 12.5 g per deciliter (interquartile range, 12.0 to 12.8) in the darbepoetin alfa group and 10.6 g per deciliter (interquartile range, 9.9 to 11.3) in the placebo group ( $P<0.001$ ) (Fig. 1). A total of 84.6% of patients in the darbepoetin alfa group and 86.9% of patients in the placebo group were switched to monthly dosing. Over the course of the study, 46% of the patients assigned to placebo received at least one dose of darbepoetin alfa as rescue therapy. The median monthly dose in patients assigned to placebo was 0  $\mu\text{g}$  (interquartile range, 0 to 5) as compared with 176  $\mu\text{g}$  (interquartile range, 104 to 305) in patients assigned to darbe-

**Table 1. Baseline Characteristics of the Patients.\***

Characteristic	Darbepoetin Alfa (N=2012)	Placebo (N=2026)	P Value†
Age (yr)			0.22
Median	68	68	
Interquartile range	60–75	60–75	
Female sex (%)	58.5	56.0	0.10
Race or ethnic group (%)‡			0.84
White	63.1	64.2	
Black	20.6	19.8	
Hispanic	13.6	13.1	
Other	2.7	3.0	
Known duration of diabetes (yr)			0.94
Median	15.3	15.5	
Interquartile range	8.2–21.8	8.4–21.7	
Body-mass index§			0.11
Median	30.5	30.1	
Interquartile range	26.3–35.5	26.2–34.9	
Retinopathy (%)	48.2	45.7	0.12
Laser treatment (%)	29.6	28.6	0.49
Diabetic neuropathy (%)	49.2	46.4	0.07
Amputation	5.7	6.1	0.58
History of cardiovascular disease (%)¶	64.0	66.9	0.05
Coronary artery disease	43.2	45.5	0.16
Heart failure	31.5	35.2	0.01
Myocardial infarction	18.4	18.3	0.95
Stroke	11.5	10.7	0.41
Peripheral arterial disease**	21.2	20.8	0.73
Use of pacemaker	4.5	6.1	0.02
Use of automatic implantable cardioverter–defibrillator	1.4	1.4	0.87
Atrial fibrillation (%)	11.0	10.0	0.29
Smoking status (%)			0.88
Current smoker	5.4	4.7	
Former smoker	38.2	39.4	
Blood pressure (mm Hg)			
Systolic			0.25
Median	136	135	
Interquartile range	122–149	123–148	
Diastolic			0.55
Median	71	70	
Interquartile range	64–80	64–80	
Serum creatinine (mg/dl)			0.01
Median	1.8	1.9	
Interquartile range	1.5–2.3	1.5–2.4	
Estimated GFR (ml/min/1.73 m <sup>2</sup> )			0.03
Median	34	33	
Interquartile range	27–43	26–42	

<b>Table 1. (Continued.)</b>			
<b>Characteristic</b>	<b>Darbepoetin Alfa (N=2012)</b>	<b>Placebo (N=2026)</b>	<b>P Value†</b>
Ratio of total protein (in mg/dl) to creatinine (in mg/dl) in urine¶			0.73
Median	0.4	0.4	
Interquartile range	0.1–2.0	0.1–1.8	
<1 (%)	65.9	64.9	
≥1 (%)	34.1	35.1	
Potassium (mmol/liter)			0.73
Median	4.7	4.7	
Interquartile range	4.3–5.1	4.3–5.1	
Albumin (g/dl)			0.13
Median	4.0	4.0	
Interquartile range	3.7–4.3	3.7–4.3	
Glycated hemoglobin (%)			0.02
Median	7.0	6.9	
Interquartile range	6.2–8.1	6.2–7.9	
Hemoglobin (g/dl)			0.15
Median	10.5	10.4	
Interquartile range	9.8–11.0	9.8–10.9	
White-cell count (×10 <sup>9</sup> /liter)			0.32
Median	6.6	6.7	
Interquartile range	5.4–8.1	5.4–8.1	
Platelet count (×10 <sup>9</sup> /liter)			0.14
Median	241	244	
Interquartile range	195–293	201–295	
Transferrin saturation (%)			0.80
Median	23	23	
Interquartile range	18–29	18–28	
Serum ferritin (μg/liter)			0.17
Median	131	137	
Interquartile range	66–254	68–263	
Cholesterol (mg/dl)			
Total			0.47
Median	169	170	
Interquartile range	142–201	142–203	
LDL			0.41
Median	84	85	
Interquartile range	64–110	63–112	
HDL			0.85
Median	46	46	
Interquartile range	38–56	38–56	
Triglycerides (mg/dl)			0.97
Median	155	154	
Interquartile range	110–230	109–230	

Table 1. (Continued.)

Characteristic	Darbepoetin Alfa (N=2012)	Placebo (N=2026)	P Value†
Medications (%)			
Insulin	48.7	49.8	0.49
Oral hypoglycemic agent	57.5	56.1	0.36
Thiazolidinedione	25.2	23.5	0.22
Sulfonamide	36.3	34.5	0.24
Biguanide	17.1	17.2	0.91
Angiotensin-converting-enzyme inhibitor or angiotensin-receptor blocker	79.7	80.0	0.82
Angiotensin-converting-enzyme inhibitor and angiotensin-receptor blocker	10.3	9.8	0.55
Beta-blocker	49.9	48.7	0.43
Aldosterone-receptor blocker	5.4	4.9	0.49
Statin	59.6	57.5	0.16
Statin or other lipid-lowering agent	64.6	64.0	0.72
Aspirin	42.0	42.8	0.63
Aspirin or other antiplatelet agent	48.0	48.6	0.68
Vitamin K antagonist	7.2	6.6	0.46
Iron			
Oral	41.8	42.7	0.57
Intravenous	1.4	1.6	0.63
Previous use of erythropoietic agent	8.8	10.2	0.14

\* All tests for baseline laboratory values were performed by a central laboratory except hemoglobin levels, which were measured at the site with the use of a hemoglobin point-of-care device. GFR denotes glomerular filtration rate, HDL high-density lipoprotein, and LDL low-density lipoprotein. To convert the values for cholesterol to millimoles per liter, multiply by 0.02586. To convert the values for triglycerides to millimoles per liter, multiply by 0.01129.

† P values have not been adjusted for multiple comparisons.

‡ Race or ethnic group was self-reported.

§ The body-mass index is the weight in kilograms divided by the square of the height in meters.

¶ These data were derived from the clinical database.

|| This category includes coronary artery disease with or without myocardial infarction, coronary-artery bypass grafting, and percutaneous coronary intervention.


\*\* This category includes peripheral arterial disease with or without peripheral arterial revascularization.

poetin alfa. Among the patients who had not died or progressed to end-stage renal disease, 93.9% of the patients in the darbepoetin alfa group and 90.4% of those in the placebo group were receiving the assigned treatment at 6 months; 87.4% and 83.7%, respectively, at 1 year; and 74.3% and 69.3%, respectively, at 2 years. There was no significant difference in the proportions of patients receiving oral iron during the study (66.8% of those in the darbepoetin alfa group and 68.6% of those in the placebo group,  $P=0.25$ ); however, more patients in the placebo group received intravenous iron (20.4%, vs. 14.8% of patients assigned to darbepoetin alfa;  $P<0.001$ ). Red-cell transfusions were administered in 297 patients in the

darbepoetin alfa group (14.8%) and in 496 patients in the placebo group (24.5%) (hazard ratio for darbepoetin alfa vs. placebo, 0.56; 95% confidence interval [CI], 0.49 to 0.65;  $P<0.001$ ).

#### PRIMARY COMPOSITE OUTCOMES AND COMPONENTS *Death, Myocardial Infarction, Unstable Angina, Heart Failure, and Stroke*

The primary cardiovascular composite outcome — death or a nonfatal cardiovascular event — occurred in 632 patients in the darbepoetin alfa group (31.4%) and in 602 patients in the placebo group (29.7%) (hazard ratio for darbepoetin alfa vs. placebo, 1.05; 95% CI, 0.94 to 1.17;  $P=0.41$ ) (Table 2 and Fig. 2A). There were no significant



between-group differences in the time to the first occurrence of the following components, when considered individually: death from any cause, fatal or nonfatal congestive heart failure, fatal or nonfatal myocardial infarction, or hospitalization for myocardial ischemia (Table 2 and Fig. 2B, 2C, and 2D). However, fatal or nonfatal stroke was more likely to occur in the patients assigned to darbepoetin alfa (101 patients [5.0%] vs. 53 patients [2.6%]; hazard ratio, 1.92; 95% CI, 1.38 to 2.68;  $P < 0.001$ ) (Table 2 and Fig. 2E).

The prespecified stratification characteristics of a history of cardiovascular disease and marked proteinuria (urinary protein-to-creatinine ratio,  $\geq 1$ ) both identified higher-risk groups regardless of the assigned treatment for the cardiovascular composite outcome. The overall null effect of darbepoetin alfa was observed in each subgroup, with no significant interaction. Similarly, there were no significant interactions for any of the other five prespecified subgroups based on age, sex, race or ethnic group, region, or baseline estimated GFR (see the Supplementary Appendix).

Cardiac revascularization procedures were performed less frequently in the patients assigned to darbepoetin alfa than in those assigned to

placebo (84 patients [4.2%] vs. 117 patients [5.8%]; hazard ratio, 0.71; 95% CI, 0.54 to 0.94;  $P = 0.02$ ).

#### Renal Outcomes

Death or end-stage renal disease occurred in 652 patients in the darbepoetin alfa group (32.4%) and in 618 patients in the placebo group (30.5%) (hazard ratio for darbepoetin alfa vs. placebo, 1.06; 95% CI, 0.95 to 1.19;  $P = 0.29$ ) (Fig. 3A). End-stage renal disease occurred in 338 patients in the darbepoetin alfa group (16.8%) and in 330 patients assigned to placebo (16.3%) (hazard ratio, 1.02; 95% CI, 0.87 to 1.18;  $P = 0.83$ ) (Fig. 3B).

The stratification characteristics of a history of cardiovascular disease and marked proteinuria also identified groups at higher risk for the composite outcome of death or end-stage renal disease, with no significant interaction in either subgroup. No significant interactions were observed in the other five prespecified subgroups, with the exception of a nominally significant interaction for race or ethnic group. The 653 patients described as nonwhite and nonblack in the darbepoetin alfa group had the greatest excess risk (hazard ratio, 1.46; 95% CI, 1.10 to

**Table 2. Composite and Component End Points.\***

End Point	Darbepoetin Alfa (N=2012) number (percent)	Placebo (N=2026) number (percent)	Hazard Ratio (95% CI)	P Value†
<b>Primary end points</b>				
Cardiovascular composite end point‡	632 (31.4)	602 (29.7)	1.05 (0.94–1.17)	0.41
Death from any cause	412 (20.5)	395 (19.5)	1.05 (0.92–1.21)	0.48
Myocardial infarction§	124 (6.2)	129 (6.4)	0.96 (0.75–1.22)	0.73
Stroke§	101 (5.0)	53 (2.6)	1.92 (1.38–2.68)	<0.001
Heart failure§	205 (10.2)	229 (11.3)	0.89 (0.74–1.08)	0.24
Myocardial ischemia	41 (2.0)	49 (2.4)	0.84 (0.55–1.27)	0.40
Renal composite end point (ESRD or death)	652 (32.4)	618 (30.5)	1.06 (0.95–1.19)	0.29
ESRD	338 (16.8)	330 (16.3)	1.02 (0.87–1.18)	0.83
<b>Additional adjudicated end points</b>				
Death from cardiovascular causes	259 (12.9)	250 (12.3)	1.05 (0.88–1.25)	0.61
Cardiac revascularization	84 (4.2)	117 (5.8)	0.71 (0.54–0.94)	0.02

\* ESRD denotes end-stage renal disease.

† P values have not been adjusted for multiple comparisons.

‡ A patient may have had multiple cardiovascular events of different types. The cardiovascular composite end point reflects only the first occurrence of any of the components.

§ This category includes both fatal and nonfatal events.

1.95); among the 2570 white patients, the hazard ratio was 1.05 (95% CI, 0.92 to 1.21), and among the 815 black patients, the hazard ratio was 0.87 (95% CI, 0.68 to 1.10;  $P=0.03$  for the interaction, uncorrected for multiple comparisons).

#### PATIENT-REPORTED OUTCOMES

The primary prespecified analysis for the patient-reported outcomes was the change from baseline to 25 weeks in the FACT-Fatigue score. Among patients with both baseline and week-25 scores, from a baseline score of 30.2 in the group of 1762 patients assigned to darbepoetin alfa and a baseline score of 30.4 in the 1769 patients assigned to placebo, there was a greater degree of improvement in the mean ( $\pm$ SD) score in the darbepoetin alfa group than in the placebo group (an increase of  $4.2\pm 10.5$  points vs.  $2.8\pm 10.3$  points,  $P<0.001$  for between-group changes). An increase of three or more points (considered to be a clinically meaningful improvement) occurred in 963 of 1762 patients assigned to darbepoetin alfa (54.7%) and 875 of 1769 patients assigned to placebo (49.5%) ( $P=0.002$ ). Other prespecified quality-of-life assessments, in the domains of energy and physical functioning as measured with the 36-Item Short-Form General Health Survey, did not differ


significantly between 1138 patients assigned to darbepoetin alfa and 1157 patients assigned to placebo (mean change in the score for energy,  $2.6\pm 9.9$  points vs.  $2.1\pm 9.7$  points;  $P=0.20$ ; mean change in the score for physical functioning,  $1.3\pm 9.2$  vs.  $1.1\pm 8.8$ ;  $P=0.51$ ).

#### BLOOD PRESSURE

There was no significant difference in systolic blood pressure between the two groups; the median systolic blood pressure over time was 134 mm Hg (interquartile range, 126 to 143) in both groups. Diastolic blood pressure was higher in the patients assigned to darbepoetin alfa than in those assigned to placebo (median over time, 73 mm Hg [interquartile range, 67 to 78] vs. 71 mm Hg [interquartile range, 65 to 77];  $P<0.001$ ).

#### PRESPECIFIED CATEGORIES OF ADVERSE EVENTS

Hypertension occurred in 491 patients in the darbepoetin alfa group and in 446 patients in the placebo group ( $P=0.07$ ) (see the Supplementary Appendix). Convulsions were reported in nine patients in the darbepoetin alfa group and in four patients in the placebo group. No cases of antibody-mediated pure red-cell aplasia were reported in either group.



**Figure 2 (facing page). Kaplan–Meier Estimates of the Probability of the Primary and Secondary End Points.**

Panel A shows the primary cardiovascular composite end point. The secondary end points of deaths from any cause (Panel B), fatal or nonfatal congestive heart failure (Panel C), fatal or nonfatal myocardial infarction and myocardial ischemia (Panel D), and fatal or nonfatal stroke (Panel E) are also shown. P values are not adjusted for multiple comparison.

Venous thromboembolic events were reported in 41 patients in the darbepoetin alfa group (2.0%), as compared with 23 patients in the placebo group (1.1%) ( $P=0.02$ ). Arterial thromboembolic events (some of which were adjudicated as cardiovascular events) were also reported more frequently in the darbepoetin alfa group (in 178 patients [8.9%] vs. 144 patients [7.1%],  $P=0.04$ ).

**CANCER**

There was no significant between-group difference in the number of patients reporting a cancer-related adverse event: 139 in the darbepoetin alfa group (6.9%) and 130 in the placebo group (6.4%) ( $P=0.53$ ). Overall, 39 deaths were attributed to cancer in the 2012 patients in the darbepoetin alfa group and 25 deaths were attributed to cancer in the 2026 patients in the placebo group ( $P=0.08$  by the log-rank test). Among patients with a history of a malignant condition at baseline, there were 60 deaths from any cause in the 188 patients assigned to darbepoetin alfa and 37 deaths in the 160 patients assigned to placebo ( $P=0.13$  by the log-rank test). In this subgroup, 14 of the 188 patients assigned to darbepoetin alfa died from cancer, as compared with 1 of the 160 patients assigned to placebo ( $P=0.002$  by the log-rank test).


**DISCUSSION**

The main purpose of the TREAT was to determine whether treatment of a low hemoglobin level with darbepoetin alfa would reduce the risk of death and major cardiovascular and renal events among patients with type 2 diabetes mellitus, chronic kidney disease, and anemia. There was no significant difference in the overall rates of either the primary cardiovascular composite end point or the primary renal composite end point with the use of the therapeutic strategy of increasing the hemoglobin level with darbepoetin alfa (to attempt to reach a target hemoglobin level of 13.0 g

per deciliter) versus placebo (with darbepoetin alfa as rescue therapy if hemoglobin values decreased below 9.0 g per deciliter). In this study involving 4038 patients randomly assigned to a study group, with 9941 patient-years of follow-up and with 1234 patients who had a composite outcome of a cardiovascular event and 1270 patients who had a composite outcome of a renal event, we found no overall significant differences in the hazard rates for these clinically important outcomes or in the rates of death, heart failure, myocardial infarction, admission for myocardial ischemia, or end-stage renal disease.

Although there was no significant increase in the overall cardiovascular composite outcome in the group assigned to darbepoetin alfa, there was an increased incidence of stroke (annualized event rate, 2.1%, vs. 1.1% in the placebo group). Data from a study of patients undergoing dialysis suggested this risk of stroke<sup>19</sup>; however, this risk was not identified in either the Correction of Hemoglobin and Outcomes in Renal Insufficiency (CHOIR) study (ClinicalTrials.gov number, NCT00211120)<sup>17</sup> or a meta-analysis.<sup>24</sup> This previously undocumented and clinically important finding of a heightened risk of stroke is not explained by an increase in systolic blood pressure. In a recent report of a randomized, placebo-controlled trial of intravenous erythropoietin in the early phase of an acute ischemic stroke,<sup>25</sup> there were more deaths in the group assigned to the ESA (42 of 256 patients [16.4%]) as compared with the group assigned to placebo (24 of 266 patients [9.0%]). This study also provides support for an adverse relationship between ESAs and stroke. We also confirmed previous findings of increased rates of venous thromboembolic events among patients treated with ESAs.

Our findings appear to differ from those of the CHOIR trial, the next largest trial involving patients with chronic kidney disease who were not undergoing dialysis, which used epoetin alfa and was discontinued prematurely after a median follow-up of 16 months and after 222 patients had a primary event.<sup>17</sup> Both groups in the CHOIR trial were randomly assigned to receive epoetin alfa, and in that study, there was a higher risk of cardiovascular events in the group assigned to a target hemoglobin level of 13.5 g per deciliter than in the group assigned to a target level of 11.3 g per deciliter (hazard ratio, 1.34; 95% CI, 1.03 to 1.74;  $P=0.03$ ). This excess of cardiovas-



cular events was largely accounted for by more deaths and heart-failure events; only 12 patients in each group had a stroke. These findings led to the suggestion that our trial should be discontinued.<sup>26</sup> However, by that time, there were more accumulated cardiovascular composite events in our trial than in the CHOIR trial, and the independent data and safety monitoring committee recommended continuation.<sup>27</sup> The TREAT executive committee updated the consent form to reflect the results from the CHOIR trial, and our patients again were asked to provide written informed consent. The final results of our study demonstrate the importance of completing the

planned follow-up of trials and the potential to draw misleading conclusions when premature discontinuation results in an insufficient number of events to allow for a reliable estimation of the effect of treatment.<sup>28,29</sup>

Before we conducted our study, there was a suggestion that ESAs might increase mortality among patients with cancer, so patients with an active malignant condition were excluded from our trial.<sup>30</sup> During the trial, mounting concern led to new regulatory warnings about the use of ESAs in patients with “anemia of cancer,”<sup>31</sup> prompting a protocol amendment to discontinue the study drug in patients in whom cancer developed. Al-

though the number of these patients did not differ significantly between the study groups, among the 348 patients with a history of cancer at baseline, mortality was higher among those assigned to darbepoetin alfa than among those assigned to placebo; these findings are consistent with those in a recent meta-analysis.<sup>32</sup>

Our trial provides long-term, placebo-controlled data on the use of ESAs in patients with diabetes, chronic kidney disease, and moderate anemia who are not undergoing dialysis. No single trial can address the multitude of pertinent issues without limitations, and our data may not be fully applicable to other patient populations. It is possible that other dosing strategies could be developed to mitigate the risk of stroke while conserving the modest benefits of treatment. In light of the baseline imbalances between the study groups, additional sensitivity analyses were conducted, and they did not alter our results. More extensive analyses of the patient-reported outcome measures are needed to assess the durability of the rather modest improvement we observed only in the FACT-Fatigue score.

The long-standing presumption of a benefit of ESAs in this patient population led to non-placebo-controlled trials, which, by design, cannot provide a reliable assessment of risk and benefit.<sup>21</sup> The present trial supplies these missing data, which may assist physicians and patients in making more informed decisions about individual care. It is our view that, in many patients with diabetes, chronic kidney disease, and moderate anemia who are not undergoing dialysis, the increased risk of stroke and possibly death among

patients with a history of a malignant condition will outweigh any potential benefit of an ESA.

Supported by Amgen, which provided independent statistical support through a contract with the board of regents for the University of Wisconsin System for data analysis for the TREAT Data and Safety Monitoring Committee as well as for the study.

Dr. Pfeffer reports receiving consulting fees from Abbott, Amgen, AstraZeneca, Biogen, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Centocor, CVRx, Genentech, Cytokinetics, Daiichi Sankyo, Genzyme, Medtronic, Novartis, Roche, Sanofi-Aventis, Servier, and VIA Pharmaceuticals and grant support from Amgen, Baxter, Celladon, Novartis, and Sanofi-Aventis, and being named coinventor on a patent for the use of inhibitors of the renin-angiotensin system in selected survivors of myocardial infarction; Dr. Burdmann, receiving consulting fees from Amgen and Sigma Pharma and grant support from Amgen and Roche; Drs. Chen and Kewalramani, being employees of and owning stock in Amgen; Dr. Cooper, receiving consulting fees from Amgen; Dr. de Zeeuw, receiving consulting fees from Amgen and Novartis and lecture fees from Amgen; Dr. Eckardt, receiving consulting fees from Amgen, Ortho Biotech, Roche, Affymax, Stada, and Sandoz-Hexal and lecture fees from Amgen, Ortho Biotech, and Roche; Dr. Ivanovich, receiving consulting fees from Amgen, Baxter, Biogen, and Reata; Dr. Levey, receiving grant support from Amgen; Dr. Lewis, receiving consulting fees from Amgen and grant support from Amgen and the Robert Wood Johnson Foundation; Dr. McGill, receiving consulting fees from Amgen and Boehringer Ingelheim, lecture fees from Novartis, and grant support from Novartis and Boehringer Ingelheim; Dr. McMurray, receiving consulting fees from Menarini, Bristol-Myers Squibb, Roche, Novocardia, Boehringer Ingelheim, Novartis, BioMérieux, and Boston Scientific, lecture fees from AstraZeneca, Solvay, Takeda, Novartis, BMS Sanofi, and Vox Media, and grant support from BMS, Novartis, Amgen, AstraZeneca, Cytokinetics, Hoffmann-La Roche, Pfizer, Scios, and GlaxoSmithKline; Dr. Parfrey, receiving consulting and lecture fees from Amgen and lecture fees from Ortho Biotech; Dr. Parving, receiving consulting fees from Amgen and Novartis and lecture fees from Novartis; Dr. Singh, receiving consulting fees from Johnson & Johnson and Watson, lecture fees from Johnson & Johnson, Amgen, and Watson, and grant support from Johnson & Johnson, Amgen, Roche, AMAG Pharmaceuticals, and Watson; Dr. Solomon, receiving grant support from Amgen; and Dr. Toto, receiving consulting and lecture fees from Amgen and grant support from Novartis, Reata, and Abbott. No other potential conflict of interest relevant to this article was reported.

#### APPENDIX

From the Department of Medicine, Brigham and Women's Hospital, Harvard Medical School (M.A.P., E.F.L., A.K.S., S.D.S.); and the Division of Nephrology, Tufts Medical Center (A.S.L.) — both in Boston; Hospital de Base, Faculdade de Medicina de São José do Rio Preto, São José do Rio Preto, Brazil (E.A.B.); Global Biostatistics and Epidemiology and Global Clinical Development, Amgen, Thousand Oaks, CA (C.-Y.C., R.K.); Baker Heart Research Institute, Melbourne, VIC, Australia (M.E.C.); the Division of Clinical Pharmacology, University Medical Center, Groningen, the Netherlands (D.Z.); the Department of Nephrology and Hypertension, University of Erlangen-Nuremberg, Erlangen, Germany (K.-U.E.); the Department of Biostatistics and Medical Informatics, University of Wisconsin, Madison (J.M.F.); the Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago (P.I.); the Department of Medicine, Washington University School of Medicine, St. Louis (J.B.M.); the Department of Cardiology, British Heart Foundation Glasgow Cardiovascular Research Centre, Glasgow, United Kingdom (J.J.V.M.); the Division of Nephrology, Health Sciences Centre, St. John's, NF, Canada (P.P.); the Department of Medical Endocrinology, Rigshospitalet, University of Copenhagen, Copenhagen, and Faculty of Health Science, Aarhus University, Aarhus (H.-H.P.) — both in Denmark; Mario Negri Institute for Pharmacological Research, Bergamo, Italy (G.R.); and the Department of Medicine, University of Texas Southwestern Medical Center, Dallas (R.T.).

The TREAT committees and teams are as follows: protocol development committee — R. Brenner and M. Pfeffer (cochairs), N. Abrouk, W. Carroll, D. Green, P. Klassen, J. Lubina, J. McMurray, L. Messer, R. Newmark, P. Parfrey, S. Solomon; executive committee — M. Pfeffer (chair), E. Burdmann, M. Cooper, D. de Zeeuw, K.-U. Eckardt, P. Ivanovich, A. Levey, J. McGill, J. McMurray, P. Parfrey, H.-H. Parving, B. Pereira, G. Remuzzi, A. Singh, S. Solomon, R. Toto; hemoglobin monitoring committee — P. Ivanovich (chair), S. Fishbane, A. Nissenson; statistical data analysis center — R. Bechhofer, D. DeMets, J. Feyzi; data and safety monitoring committee — C. Hennekens (chair), G. Chertow, E. Frohlich, P. O'Brien, J. Rouleau; clinical end-point center — S. Solomon (chair), E. Lewis (cochair), A. Desai, C. Duong, P. Finn, L.H. Hartley, S. Kesari, J. Lin, J. Meadows, L. Mielniczuk, F. Shamshad, A. Singh, O. Vasyleyeva, L. Weinrauch; study team — A. Adee, A. Ahmed, P. Blaisdell, P. Brady, L. Bucker, J. Cap, W. Carroll, D. Chaparro, C.-Y. Chen, B. Condon, R.

Cravario, R. Damato, K. Dellacroce, K. DiRocco, D. Donovan, B. Doria, M. Dougherty, J. Droge, A. Grewal, L. Guimaraes, P. Haynes, J. Hevy, T. Jambusaria, N. James, A. Kacprzak, M. Kasenda, S.R.K. Reddy, R. Kewalramani, H. Kirby, C. Klacker, T. Kocsis, A. Kondo, M. Lauw, M. Liebelt, P. McElligott, B. Mesquita, C. Mix, A. Mueller, S. O'Callaghan, H. Ocampo, K. Olson, S. Perez, J. Pillai, A. Pollock, F. Poloni, K. Polu, R. Poston, G. Ramirez, A. Rasmussen, L. Reeves, M. Rocha, A.P. Ross, J. Rossert, B. Sahl, T. See, S. Shahinfar, K. Shart, C. Stehman-Breen, A. Teh, L. Tierra, M. Vaghela, C. White. Enrollment by country was as follows (numbers of patients are in parentheses): Argentina (84), Australia (58), Austria (3), Brazil (190), Bulgaria (28), Canada (176), Chile (14), Czech Republic (96), Denmark (10), Estonia (16), France (11), Germany (135), Hungary (70), Italy (87), Latvia (51), Mexico (150), Poland (213), Portugal (17), Romania (47), Russia (117), Slovakia (65), Slovenia (12), United Kingdom (49), United States (2339).

## REFERENCES

1. Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. *Diabetes Care* 1993; 16:434-44.
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. *Lancet* 2006;368:29-36.
3. Turnbull F, Neal B, Algert C, et al. Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. *Arch Intern Med* 2005;165:1410-9.
4. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. *Lancet* 2005;366: 1267-78. [Errata, *Lancet* 2005;366:1358, 2008;371:2084.]
5. Gaede P, Lund-Andersen H, Parving H-H, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. *N Engl J Med* 2008;358:580-91.
6. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. *N Engl J Med* 2001;345:861-9.
7. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. *N Engl J Med* 2001;345:851-60.
8. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. *Circulation* 2005;112:171-8.
9. Locatelli F, Pisoni RL, Combe C, et al. Anaemia in haemodialysis patients of five European countries: association with morbidity and mortality in the Dialysis Outcomes and Practice Patterns Study (DOPPS). *Nephrol Dial Transplant* 2004;19:121-32. [Erratum, *Nephrol Dial Transplant* 2004; 19:1666.]
10. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC, Barre PE. The impact of anemia on cardiomyopathy, morbidity, and mortality in end-stage renal disease. *Am J Kidney Dis* 1996;28:53-61.
11. Keane WF, Brenner BM, de Zeeuw D, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. *Kidney Int* 2003;63:1499-507.
12. Vlagopoulos PT, Tighiouart H, Weiner DE, et al. Anemia as a risk factor for cardiovascular disease and all-cause mortality in diabetes: the impact of chronic kidney disease. *J Am Soc Nephrol* 2005;16: 3403-10.
13. Tong PCY, Kong APS, So W-Y, et al. Hematocrit, independent of chronic kidney disease, predicts adverse cardiovascular outcomes in Chinese patients with type 2 diabetes. *Diabetes Care* 2006;29: 2439-44.
14. Pfeffer MA, Solomon SD, Singh AK, Ivanovich P, McMurray JJ. Uncertainty in the treatment of anemia in chronic kidney disease. *Rev Cardiovasc Med* 2005;Suppl 3: S35-S41.
15. Eschbach JW, Abdulhadi MH, Browne JK, et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease: results of a phase III multicenter clinical trial. *Ann Intern Med* 1989;111:992-1000.
16. Canadian Erythropoietin Study Group. Association between recombinant human erythropoietin and quality of life and exercise capacity of patients receiving haemodialysis. *BMJ* 1990;300:573-8.
17. Singh AK, Szczech L, Tang KL, et al. Correction of anemia with epoetin alfa in chronic kidney disease. *N Engl J Med* 2006;355:2085-98.
18. Drueke TB, Locatelli F, Clyne N, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. *N Engl J Med* 2006;355:2071-84.
19. Parfrey PS, Foley RN, Wittreich BH, Sullivan DJ, Zagari MJ, Frei D. Double-blind comparison of full and partial anemia correction in incident hemodialysis patients without symptomatic heart disease. *J Am Soc Nephrol* 2005;16:2180-9.
20. Phrommintikul A, Haas SJ, Elsik M, Krum H. Mortality and target haemoglobin concentrations in anemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. *Lancet* 2007; 369:381-8.
21. Pfeffer MA. Critical missing data in erythropoiesis-stimulating agents in CKD: first beat placebo. *Am J Kidney Dis* 2008; 51:366-9.
22. Pfeffer MA, Burdmann EA, Chen CY, et al. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *Am J Kidney Dis* 2009;54:59-69.
23. Mozzicato P. Standardised MedDRA queries: their role in signal detection. *Drug Saf* 2007;30:617-9.
24. Strippoli GF, Navaneethan SD, Craig JC. Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease. *Cochrane Database Syst Rev* 2006;4: CD003967.
25. Ehrenreich H, Weissenborn K, Prange H, et al. Recombinant human erythropoietin in the treatment of acute ischemic stroke. *Stroke* 2009 October 15 (Epub ahead of print).
26. Strippoli GFM, Tognoni G, Navaneethan SD, Nicolucci A, Craig JC. Hemoglobin targets: we were wrong, time to move on. *Lancet* 2007;369:349-50.
27. Pfeffer MA. An ongoing study of anemia correction in chronic kidney disease. *N Engl J Med* 2007;356:959-61.
28. DeMets DL, Pocock SJ, Julian DG. The agonising negative trend in monitoring of clinical trials. *Lancet* 1999;354:1983-8.
29. Califf RM, DeMets DL. Principles from clinical trials relevant to clinical practice: Part I. *Circulation* 2002;106:1015-21.
30. Leyland-Jones B, Semiglazov V, Pawlicki M, et al. Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. *J Clin Oncol* 2005;23:5960-72.
31. FDA black box warning for Aranesp. Silver Spring, MD: Food and Drug Administration. (Accessed October 23, 2009, at [http://www.accessdata.fda.gov/drugsatfda\\_docs/label/2008/103951s195PI.pdf](http://www.accessdata.fda.gov/drugsatfda_docs/label/2008/103951s195PI.pdf))
32. Bohlius J, Schmidlin K, Brillant C, et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. *Lancet* 2009;373:1532-42. [Erratum, *Lancet* 2009;374:28.]

Copyright © 2009 Massachusetts Medical Society.